Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1657 1673 1693
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18439034 | STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18029470 | ENDOSOMAL ESCAPE DOMAINS FOR DELIVERY OF MACROMOLECULES INTO CELLS | Non-Final OA | The Regents of the University of California |
| 18675302 | ENZYMATIC SYNTHESIS OF 4'-ETHYNYL NUCLEOSIDE ANALOGS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18423652 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18253419 | COMPOSITIONS AND METHODS USING A COMBINATION OF OLEUROPEIN AND QUERCETIN FOR CELLULAR ENERGY | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18393220 | METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES | Non-Final OA | Illumina, Inc. |
| 18252394 | MODIFIED SOPHOROLIPID FOR IMPROVED BIOAVAILABILITY OF AMINO ACIDS AND METHOD OF USE | Final Rejection | LOCUS SOLUTIONS IPCO, LLC |
| 18022855 | PROCESS FOR THE DIRECT CONVERSION OF CELLULOSE TO GLYCOLS USING NON-NOBLE METAL LOADED ZEOLITE CATALYSTS | Non-Final OA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH |
| 18703219 | THERAPEUTICALLY EFFECTIVE COMBINATION OF A FLT3 INHIBITOR AND A BCL-2 INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | Non-Final OA | Hanmi Pharm. Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy